Clinical Study to Evaluate the Safety and Efficacy of Single Dose Intravenous Infusion of CRISPR/Cas9-edited Autologous CD34 + Hematopoietic Stem/Progenitor Cells (BRL-101) in the Treatment of Severe Sickle Cell Disease is a NA clinical asset sponsored by Bioray Laboratories in Sickle Cell Disease. SEO and diligence focus: BRL-101, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.